Scottish ProStrakan, JapanBridge Ink Sancuso Licensing Deal For Japan, China, And Southeast Asia
This article was originally published in PharmAsia News
SHANGHAI - Scotland-based ProStrakan Group has granted JapanBridge K.K. an exclusive license to develop and commercialize antiemetic Sancuso (granisetron) in Japan, mainland China, Taiwan, Singapore and Malaysia, the companies announced May 23
You may also be interested in...
Kyowa Hakko Kirin and Solasia Pharma are rolling out the first result of their partnership to bring Western oncology products to Asia, announcing a commercialization agreement that grants Kyowa Hakkko Kirin rights to sell ProStrakan's extended release transdermal Sancuso in some Asian countries
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).